Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion

Retina

Volumn 31, Issue 2, 2011, Pages 290-297

  Sonoda, Yasushi ^a   Arimura, Noboru ^a   Shimura, Masahiko ^b   Sakamoto, Taiji ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b NTT East Tohoku Hospital   (Japan)

Author keywords

antibody; cystoids macular edema; Diabetic retinopathy; drug mechanism; intravitreous injection; vascular endothelial growth factor

Indexed keywords

ANTIGLAUCOMA AGENT; BEVACIZUMAB; EYE DROPS; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DIABETIC RETINOPATHY; DRUG EFFECT; FEMALE; FILTERING OPERATION; HUMAN; INTERVENTION STUDY; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; LASER COAGULATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTICAL COHERENCE TOMOGRAPHY; PREOPERATIVE EVALUATION; RETINA MACULA LUTEA; RETINA VEIN OCCLUSION; VISUAL ACUITY; VITREOUS BODY DETACHMENT;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; TOMOGRAPHY, OPTICAL COHERENCE; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79551512856     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181eef070     Document Type: Article

References (40)

1. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-250.
2. Ip MS, Kumar KS. Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion. Arch Ophthalmol 2002;120:1217-1219.
3. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002;240: 782-783.
4. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008;92:76-80..
5. Diabetic Retinopathy Clinical Research Network. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: A pilot study. Ophthalmology 2007;114:1190-1196.
6. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: Two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-1538.
7. Yilmaz T, Weaver CD, Gallagher MJ, et al. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: A systematic review. Ophthalmology 2009;116:902-911.
8. Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev 2008; CD005656.
9. Charmandari E, Kino T, Ichijo T, Chrousos GP. Generalized glucocorticoid resistance: Clinical aspects, molecular mechanisms and implications of a rare genetic disorder. J Clin Endocrinol Metab 2008;93:1563-1572.
10. Zhou J, Cidlowski JA. The human glucocorticoid receptor: One gene, multiple proteins and diverse responses. Steroids 2005; 70:407-417.
11. Schaaf MJ, Cidlowski JA. Molecular mechanisms of glucocorticoid action and resistance. J Steroid Biochem Mol Biol 2002;83:37-48.
12. McAllister IL, Vijayasekaran S, Chen SD, Yu DY. Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol 2009;147:838-846.
13. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC. Intravitreal triamcinolone acetonide inhibits breakdown of the bloodretinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 2008;57: 1026-1033.
14. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of bloodretinal and blood-aqueous barrier breakdown. Exp Eye Res 2005;80:249-258.
15. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005; 46:1440-1444.
16. Arimura N, Otsuka H, Yamakiri K, et al. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Ophthalmology 2009;119:921-926.
17. Butler JM, Guthrie SM, Koc M, et al. SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J Clin Invest 2005;115:86-93.
18. Wehling M, Lösel R. Non-genomic steroid hormone effects: Membrane or intracellular receptors? J Steroid Biochem Mol Biol 2006;102:180-183.
19. Tasker JG, Di S, Malcher-Lopes R. Minireview: Rapid glucocorticoid signaling via membrane-associated receptors. Endocrinology 2006;147:5549-5556.
20. Makara GB, Haller J. Non-genomic effects of glucocorticoids in the neural system. Evidence, mechanisms and implications. Prog Neurobiol 2001;65:367-390.
21. Schmidt BM. Rapid non-genomic effects of aldosterone on the renal vasculature. Steroids 2008;73:961-965.
22. Miyamoto N, Iossifov D, Metge F, Behar-Cohen F. Early effects of intravitreal triamcinolone on macular edema: Mechanistic implication. Ophthalmology 2006;113:2048-2053.
23. Ito M, Okubo A, Sonoda Y, Yamakiri K, Sakamoto T. Intravitreal triamcinolone acetonide for exudative age-related macular degeneration among Japanese patients. Ophthalmologica 2006;220:118-124.
24. Shimonagano Y, Makiuchi R, Miyazaki M, Doi N, Uemura A, Sakamoto T. Results of visual acuity and foveal thickness in diabetic macular edema after vitrectomy. Jpn J Ophthalmol 2007;51:204-209.
25. Masuyama K, Yamakiri K, Arimura N, Sonoda Y, Doi N, Sakamoto T. Posturing time after macular hole surgery modified by optical coherence tomography images: A pilot study. Am J Ophthalmol 2009;147:481-488.
26. Marmor MF. Mechanisms of fluid accumulation in retinal edema. Doc Ophthalmol 1999;97:239-249.
27. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: More than meets the eye. Surv Ophthalmol 2002;47:S253-S262.
28. Pannicke T, Iandiev I, Wurm A, et al. Diabetes alters osmotic swelling characteristics and membrane conductance of glial cells in rat retina. Diabetes 2006;55:633-639.
29. Matsuda S, Gomi F, Oshima Y, Tohyama M, Tano Y. Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol Vis Sci 2007;46: 1062-1068.
30. Brooks HL Jr, Caballero S Jr, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol 2004;122:1801-1807.
31. Mizuno S, Nishiwaki A, Morita H, Miyake T, Ogura Y. Effects of periocular administration of triamcinolone acetonide on leukocyte-endothelium interactions in the ischemic retina. Invest Ophthalmol Vis Sci 2007;48:2831-2836.
32. Derevjanik NL, Vinores SA, Xiao WH, et al. Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest Ophthalmol Vis Sci 2002;43:2462-2467.
33. Nakao S, Hata Y, Miura M, et al. Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: Role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis. Am J Pathol 2007;171:1058-1065.
34. Sears JE, Hoppe G. Triamcinolone acetonide destabilizes VEGF mRNA in Müller cells under continuous cobalt stimulation. Invest Ophthalmol Vis Sci 2005;46:4336-4341.
35. Uckermann O, Kutzera F, Wolf A, et al. The glucocorticoid triamcinolone acetonide inhibits osmotic swelling of retinal glial cells via stimulation of endogenous adenosine signaling. J Pharmacol Exp Ther 2005;315:1036-1045.
36. Wurm A, Iandiev I, Hallborn M, et al. Purinergic receptor activation inhibits osmotic glial cell swelling in the diabetic rat retina. Exp Eye Res 2008;87:385-393.
37. Stefansson E. Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol 2006;51:364-380.
38. Paques M, Krivosic V, Girmens JF, et al. Decreased venous tortuosity associated with resolution of macular edema after intravitreal injection of triamcinolone. Retina 2005;25: 1099-1101.
39. Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008;145:854-861.
40. Welch DE, Elmariah H, Peden MC, Adams SG, Ratnakaram R, Kaushal S. Short-term response of macular edema to intravitreal bevacizumab. Br J Ophthalmol 2009;93:1033-1036.